<DOC>
	<DOCNO>NCT00099281</DOCNO>
	<brief_summary>The purpose trial study DPPE combine epirubicin cyclophosphamide patient metastatic and/or recurrent breast cancer may receive previous hormone treatment exposure anthracycline treatment . Stratification allocation within follow subgroup : 1 . Prior cytotoxic treatment ; 2 . Estrogen receptor status ; 3 . ECOG performance status ; 4 . Number cycle chemotherapy .</brief_summary>
	<brief_title>DPPE Combination With Epirubicin Cyclophosphamide Treatment Breast Cancer</brief_title>
	<detailed_description>Endpoints trial follow : primary : overall survival ; secondary : response rate , progression free survival , toxicity , neurocognitive function .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Histological proof breast cancer Documented evidence metastatic and/or recurrent breast cancer Presence least one bidimensional unidimensional lesion ECOG status 0 , 1 2 Quality life</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Metastatic breast cancer</keyword>
</DOC>